Minovia Therapeutics’ MNV-201 Granted FDA Fast Track Designation for Myelodysplastic Syndrome

Minovia Therapeutics Ltd., a clinical-stage biotech focused on mitochondrial diseases and age-related conditions, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its lead investigational drug, MNV-201, for the treatment of Myelodysplastic Syndrome (MDS). MDS is a serious, age-related blood disorder affecting hematopoiesis, the process by which blood cells are formed.

This new Fast Track status for MNV-201 complements existing FDA Fast Track and Rare Pediatric Disease Designations granted for the drug’s use in treating Pearson Syndrome, a rare and life-threatening mitochondrial disorder in children. Minovia is currently conducting a Phase 2 clinical trial for MNV-201 in Pearson Syndrome.

Natalie Yivgi-Ohana, Minovia’s Co-founder and CEO, highlighted the importance of the designation: “The Fast Track Designation in MDS validates the urgency and potential of our mitochondrial-targeting science. FDA designations like this can accelerate development timelines and offer valuable benefits throughout the regulatory process.”

The FDA’s Fast Track program is designed to speed up the review of treatments for serious conditions with unmet medical needs. Benefits include more frequent FDA interactions, eligibility for priority review, and the option for rolling submission of a future Biologics License Application (BLA) for MNV-201.

Separately, Minovia recently entered into a definitive business combination agreement with Launch One Acquisition Corp. (Nasdaq: LPAA), a special purpose acquisition company. The transaction is expected to close in late 2025, after which the combined company will operate as Minovia Therapeutics and be listed on Nasdaq under a new ticker symbol.